Shopping Cart 0
Cart Subtotal
USD 0

UroGen Pharmaceuticals Ltd (URGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

UroGen Pharmaceuticals Ltd (UroGen Pharma), formerly TheraCoat Ltd is a clinical-stage biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The company's pipeline products comprise drug candidates for various forms of non-muscle invasive urothelial cancer including low grade bladder cancer, carcinoma in situ bladder cancer and low grade upper tract urothelial carcinoma. It utilizes proprietary platform technologies such as RTGel, based formulation of Botox, an investigational new drug being studied for the treatment of overactive bladder (OB) and interstitial cystitis (IC). The company performs clinical trials in various urinary tract indications such as UTUC and bladder cancer in centers in the US, Europe and Israel. UroGen Pharma is headquartered in Ra'anana, Israel.

UroGen Pharmaceuticals Ltd (URGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

UroGen Pharma Acquires All Intellectual Property Assets From Telormedix 12

Venture Financing 13

TheraCoat to Raise USD20 Million in Venture Financing 13

TheraCoat Raises USD 7 Million In Venture Financing 14

Licensing Agreements 15

Allergan Enters Into Licensing Agreement With UroGen Pharma 15

Equity Offering 16

UroGen Pharma Raises USD69 Million in Public Offering of Shares 16

UroGen Pharma Raises USD67 Million in IPO 18

UroGen Pharmaceuticals Ltd-Key Competitors 20

UroGen Pharmaceuticals Ltd-Key Employees 21

UroGen Pharmaceuticals Ltd-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Aug 14, 2018: UroGen Pharma reports second quarter 2018 financial results and recent corporate developments 23

Aug 08, 2018: UroGen Pharma appoints Peter P. Pfreundschuh as Chief Financial Officer 25

May 15, 2018: UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments 26

Nov 14, 2017: UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments 27

Corporate Communications 28

Sep 11, 2018: UroGen Pharma names Jones Woody Bryan as Senior Vice President of Business Development 28

Jul 10, 2018: UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors 29

Feb 14, 2018: UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as COO 30

Dec 12, 2017: UroGen Pharma Expands Clinical Development Leadership Team 31

Nov 02, 2017: UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors 32

May 16, 2017: UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors 33

Apr 24, 2017: UroGen Pharma Welcomes New Board Member Kate Falberg 34

Product News 35

05/11/2017: UroGen Pharma Announces Data Presentation Related to its Clinical Stage Uro-Oncology Candidate VesiGel at the American Urology Association 2017 Annual Meeting 35

05/11/2017: UroGen Pharma Announces Data Presentation Related to its Clinical Stage Uro-Oncology Candidate Vesimune at the American Urology Association 2017 Annual Meeting 36

Clinical Trials 37

Apr 03, 2018: UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) 37

Nov 27, 2017: UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting 38

Aug 29, 2017: UroGen Pharma Receives FDA Fast Track Designation for MitoGel for the Treatment of Upper Tract Urothelial Carcinoma (UTUC) 39

Apr 03, 2017: UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel for Treatment of Low-Grade Upper Tract Urothelial Carcinoma 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

UroGen Pharma Acquires All Intellectual Property Assets From Telormedix 12

TheraCoat to Raise USD20 Million in Venture Financing 13

TheraCoat Raises USD 7 Million In Venture Financing 14

Allergan Enters Into Licensing Agreement With UroGen Pharma 15

UroGen Pharma Raises USD69 Million in Public Offering of Shares 16

UroGen Pharma Raises USD67 Million in IPO 18

UroGen Pharmaceuticals Ltd, Key Competitors 20

UroGen Pharmaceuticals Ltd, Key Employees 21

UroGen Pharmaceuticals Ltd, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

UroGen Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

UroGen Pharmaceuticals Ltd (UroGen Pharma), formerly TheraCoat Ltd is a clinical-stage biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The company's pipeline products comprise drug candidates for various forms of non-muscle invasive urothelial cancer including low grade bladder cancer, carcinoma in situ bladder cancer and low grade upper tract urothelial carcinoma. It utilizes proprietary platform technologies such as RTGel, based formulation of Botox, an investigational new drug being studied for the treatment of overactive bladder (OB) and interstitial cystitis (IC). The company performs clinical trials in various urinary tract indications such as UTUC and bladder cancer in centers in the US, Europe and Israel. UroGen Pharma is headquartered in Ra'anana, Israel.

UroGen Pharmaceuticals Ltd (URGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

UroGen Pharma Acquires All Intellectual Property Assets From Telormedix 12

Venture Financing 13

TheraCoat to Raise USD20 Million in Venture Financing 13

TheraCoat Raises USD 7 Million In Venture Financing 14

Licensing Agreements 15

Allergan Enters Into Licensing Agreement With UroGen Pharma 15

Equity Offering 16

UroGen Pharma Raises USD69 Million in Public Offering of Shares 16

UroGen Pharma Raises USD67 Million in IPO 18

UroGen Pharmaceuticals Ltd-Key Competitors 20

UroGen Pharmaceuticals Ltd-Key Employees 21

UroGen Pharmaceuticals Ltd-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Aug 14, 2018: UroGen Pharma reports second quarter 2018 financial results and recent corporate developments 23

Aug 08, 2018: UroGen Pharma appoints Peter P. Pfreundschuh as Chief Financial Officer 25

May 15, 2018: UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments 26

Nov 14, 2017: UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments 27

Corporate Communications 28

Sep 11, 2018: UroGen Pharma names Jones Woody Bryan as Senior Vice President of Business Development 28

Jul 10, 2018: UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors 29

Feb 14, 2018: UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as COO 30

Dec 12, 2017: UroGen Pharma Expands Clinical Development Leadership Team 31

Nov 02, 2017: UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors 32

May 16, 2017: UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors 33

Apr 24, 2017: UroGen Pharma Welcomes New Board Member Kate Falberg 34

Product News 35

05/11/2017: UroGen Pharma Announces Data Presentation Related to its Clinical Stage Uro-Oncology Candidate VesiGel at the American Urology Association 2017 Annual Meeting 35

05/11/2017: UroGen Pharma Announces Data Presentation Related to its Clinical Stage Uro-Oncology Candidate Vesimune at the American Urology Association 2017 Annual Meeting 36

Clinical Trials 37

Apr 03, 2018: UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) 37

Nov 27, 2017: UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting 38

Aug 29, 2017: UroGen Pharma Receives FDA Fast Track Designation for MitoGel for the Treatment of Upper Tract Urothelial Carcinoma (UTUC) 39

Apr 03, 2017: UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel for Treatment of Low-Grade Upper Tract Urothelial Carcinoma 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UroGen Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

UroGen Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

UroGen Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

UroGen Pharma Acquires All Intellectual Property Assets From Telormedix 12

TheraCoat to Raise USD20 Million in Venture Financing 13

TheraCoat Raises USD 7 Million In Venture Financing 14

Allergan Enters Into Licensing Agreement With UroGen Pharma 15

UroGen Pharma Raises USD69 Million in Public Offering of Shares 16

UroGen Pharma Raises USD67 Million in IPO 18

UroGen Pharmaceuticals Ltd, Key Competitors 20

UroGen Pharmaceuticals Ltd, Key Employees 21

UroGen Pharmaceuticals Ltd, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

UroGen Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.